IPIX - Innovation Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0800
+0.0040 (+5.26%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Previous Close0.0760
Open0.0825
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0760 - 0.0890
52 Week Range0.0700 - 0.4400
Volume650,814
Avg. Volume291,473
Market Cap17M
Beta (3Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Innovation Pharmaceuticals:  Oral Cancer on the Rise; Company Offers Perspectives on Opportunity of Brilacidin for the Prevention of Oral Mucositis

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to provide perspectives on the unmet patient need in OM and global commercial opportunity of Brilacidin, the Company’s defensin-mimetic drug candidate, for the prevention of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation. “Quite simply, OM is a significant unmet patient need in supportive cancer care, with a sizable commercial opportunity attached to delivering novel OM therapies,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals.

  • GlobeNewswire

    Innovation Pharmaceuticals Highlights Preclinical Data by Independent Cancer Researchers Supporting p53 Drug Candidate Kevetrin’s Potential in Treating Acute Myeloid Leukemia

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to highlight preclinical data by independent cancer researchers supporting the therapeutic potential of Kevetrin, the Company’s novel p53-modulating anti-cancer drug candidate, in treating Acute Myeloid Leukemia (AML). Building on Kevetrin data in AML presented at the 2017 European Hematology Association (EHA) Annual Meeting, a group of independent cancer researchers recently presented additional data at the June 2019 EHA Annual Meeting, and at the October 2019 Italian Society of Hematology Annual Meeting.

  • GlobeNewswire

    Innovation Pharmaceuticals Partnering Provides Momentum For Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient Need

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce positive momentum in its efforts to advance programs utilizing Brilacidin for Inflammatory Bowel Disease (IBD).  The Company’s goal is to develop Brilacidin as a novel, non-corticosteroid, non-biologic orally-delivered drug capable of treating a wide continuum of GI diseases, to the benefit of patients and shareholders alike. The first Joint Development Committee (JDC) meeting with Alfasigma S.p.A.—an Italy-based global pharmaceutical company that licensed worldwide rights to develop Brilacidin for localized treatment in Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS)—was recently convened.

  • GlobeNewswire

    Innovation Pharmaceuticals Cites Recent Academic Literature Showing Host Defense Proteins at Cutting-Edge of Medicine for Multiple Diseases

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of published Host Defense Protein/Peptide (HDP) basic research insights that reinforce the therapeutic potential of Brilacidin, the Company’s novel HDP-mimetic drug candidate.

  • GlobeNewswire

    Innovation Pharmaceuticals Clinical Trial of Oral Brilacidin in Ulcerative Colitis Program Expected to Commence in December; Top-Line Data in Q1 2020

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that management is finalizing documentation necessary to initiate the planned Phase 1 clinical trial of oral Brilacidin in its Ulcerative Colitis (UC) program. Document submissions are expected to be completed early in October, keeping the clinical trial on track for commencement in December. The study evaluating Brilacidin in tablet form in healthy volunteers will be the first in a series of clinical trials, effectively launching the Company’s UC clinical program in the anchored Brilacidin franchise.

  • GlobeNewswire

    Innovation Pharmaceuticals Engages Locust Walk, A Global Life Sciences Transaction Firm

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the Company has engaged Locust Walk, a leading global life sciences transaction firm. Locust Walk will seek to assist the Company in maximizing the value of its assets.

  • GlobeNewswire

    Innovation Pharmaceuticals Announces Successful Formulation of Oral Brilacidin Tablets; Upcoming Clinical Trial to Target Delivery to the Colon

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that BDD Pharma, the Company’s formulation partner in the area of Inflammatory Bowel Disease (IBD), has performed appropriate non-clinical studies that show the oral dosage form meets in vitro specifications for selective delivery of oral Brilacidin to the colon. Brilacidin tablet design employs BDD Pharma’s patented OralogiK™ technology to provide controlled erosion of a time-dependent barrier layer during small intestine transit. The first clinical trial of oral Brilacidin in the Company’s Ulcerative Colitis program is planned to commence in December 2019 in healthy volunteers in the United Kingdom.

  • GlobeNewswire

    Innovation Pharmaceuticals Plans for Clinical Trial of Oral Brilacidin for Ulcerative Colitis Program in 4th Quarter 2019

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the Company is planning for the first human trial utilizing an oral formulation of Brilacidin in the program for Ulcerative Colitis (UC), a common type of Inflammatory Bowel Disease (IBD), in December 2019. Brilacidin is the lead drug candidate in the Company’s portfolio of novel compounds called defensin-mimetics, which are modeled on the body’s host defense response and exhibit immunomodulatory, anti-inflammatory and anti-infective properties.

  • GlobeNewswire

    Innovation Pharmaceuticals Provides Corporate Update Highlighting Clinical Pipeline Progress and Business Development Activities

    Company building on momentum from recently executed licensing agreement with Alfasigma S.p.A. BEVERLY, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update highlighting recent accomplishments, clinical pipeline progress, and ongoing business development activities across its first-in-class drug candidates, Brilacidin and Kevetrin. “We are pleased with our accomplishments, thus far, in 2019, and are committed to advancing the clinical development of our pipeline,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals.

  • GlobeNewswire

    Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has executed a license agreement with Alfasigma S.p.A (“Alfasigma”) to develop and commercialize locally-administered Brilacidin (e.g., foam, enema, gel), on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). The Company will receive from Alfasigma an initial payment, plus be eligible for additional payments based on certain milestones, totaling over $24 million, and receive a 6 percent royalty (net sales) based on the successful marketing of Brilacidin for UP/UPS. The agreement also includes a Right of First Refusal for Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for Brilacidin in other Gastrointestinal indications.

  • GlobeNewswire

    Innovation Pharmaceuticals Signs Agreement for Advanced Oral Tablet Technology in Treating Inflammatory Bowel Disease

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, has signed an agreement with BDD Pharma, an award-winning drug delivery company specializing in modified and controlled release oral formulations, to immediately begin the development of tablets for targeted oral delivery of Brilacidin to the colon. BDD’s OralogiK™ technology has been specifically designed to work independently of variations in the GI tract and has shown accurate and consistent performance in clinical studies in several hundred subjects.

  • GlobeNewswire

    Innovation Pharmaceuticals to Attend 2019 BIO International Convention, June 3-6

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company will be attending the 2019 BIO International Convention, held June 3-6, in Philadelphia, Pennsylvania. The three day-long conference is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

  • GlobeNewswire

    Innovation Pharmaceuticals At Digestive Disease Week Conference, Nears Selecting Drug Formulation Company to Prepare Oral Brilacidin for Targeted Delivery in Ulcerative Colitis

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the Company attended the annual Digestive Disease Week® (DDW) Conference held at the San Diego Convention Center in San Diego, California from May 18-21, 2019. DDW is the world's leading educational forum for academicians, clinicians, researchers, students and trainees working in gastroenterology, hepatology, GI endoscopy, gastrointestinal surgery and related fields.  Innovation Pharmaceuticals held constructive meetings covering the next stages of the Company’s pipeline development, aiming for advancement of Brilacidin in Inflammatory Bowel Disease (IBD), including Ulcerative Colitis (UC) and Crohn’s Disease (CD).

  • GlobeNewswire

    Innovation Pharmaceuticals Announces Non-Binding Term Sheet Signed with Global Pharmaceutical Company to Develop and Commercialize Brilacidin for the Treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has signed a non-binding term sheet with a global pharmaceutical company to develop and commercialize locally-administered Brilacidin (e.g., foam, enema, gel), on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. The non-binding term sheet also includes a Right of First Refusal for rights to Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease, such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for rights to Brilacidin in other Gastrointestinal (GI) indications.

  • GlobeNewswire

    Innovation Pharmaceuticals Receives FDA End-of-Phase 2 Meeting Minutes

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today it has received Food and Drug Administration (FDA) End-of-Phase 2 (EoP2) meeting minutes, helping to guide the Company’s planned Phase 3 program for Brilacidin oral rinse to decrease the incidence of Severe Oral Mucositis (SOM) (WHO Grade ≥3) in Head and Neck Cancer (HNC) patients receiving chemoradiation. Brilacidin oral rinse is being developed under FDA Fast Track designation for Oral Mucositis (OM).

  • GlobeNewswire

    Innovation Pharmaceuticals - "JAMA" Article Reinforces Need for Novel Oral Mucositis Treatments in Supportive Cancer Care; Company progresses through first stage of review by European Medicines Agency (EMA) regarding Scientific Advice for planned Phase 3 Program

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of a recent publication in the Journal of the American Medical Association (JAMA), a leading independent, international journal for medical professionals, detailing data from a clinical study1 on the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo on radiotherapy-related oral mucositis pain. A corresponding editorial2, titled, “The Search for an Effective Therapy and Pain Relief for Oral Mucositis,” accompanied the article.

  • GlobeNewswire

    Innovation Pharmaceuticals Reports p53 Drug Candidate Therapeutic Potential Further Supported by Academic Research in Leukemias and in Combination with Cancer Immunotherapies

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report recent academic and pre-clinical research further supports the therapeutic potential of Kevetrin, the Company’s p53 drug candidate, in leukemias and in combination with cancer immunotherapies. Kevetrin has been successfully evaluated in a Phase 1 clinical trial in advanced solid tumors and a Phase 2a clinical trial in late-stage ovarian cancer.

  • GlobeNewswire

    Innovation Pharmaceuticals Reports Enhancements in Manufacture of Brilacidin Phase 3 Drug Supply

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has implemented yield and purity enhancements in the manufacturing of Brilacidin for the bulk production of Phase 3 drug supply using the Quality by Design approach. The Company is now positioning itself to further advance Brilacidin, most immediately, in its planned Phase 3 Oral Mucositis program, and in mid-stage testing for Inflammatory Bowel Disease.

  • GlobeNewswire

    Innovation Pharmaceuticals European Subsidiary, IPIX Pharma Ltd., Granted Meeting with European Medicines Agency (EMA) to Discuss International Phase 3 Brilacidin Oral Mucositis Program

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted a meeting with the Company’s European subsidiary, IPIX Pharma Ltd., to discuss a briefing package submitted for Scientific Advice regarding the clinical development program of Brilacidin oral rinse to decrease the incidence of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.

  • GlobeNewswire

    Innovation Pharmaceuticals Requesting European Medicines Agency (EMA) Input for International Phase 3 Brilacidin Oral Mucositis Program

    Innovation Pharmaceuticals, (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that necessary documentation has been completed for the European Medicines Agency (EMA) March 15, 2019 submission cycle requesting Scientific Advice to advance Brilacidin oral rinse in a Phase 3 program for the prevention of severe Oral Mucositis (OM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.  The documentation is being submitted to the EMA through IPIX Pharma, Ltd., the Innovation Pharmaceuticals Irish subsidiary.

  • GlobeNewswire

    Innovation Pharmaceuticals Forms Irish Subsidiary to Facilitate International Development of Clinical Pipeline

    Innovation Pharmaceuticals, (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Companies Registration Office Ireland has provided notification that the Company’s subsidiary, IPIX Pharma Limited, is registered under the Companies Act 2014, effective February 15, 2019. As Innovation Pharmaceuticals will now be engaging the European Medicines Agency (EMA) to advance its clinical pipeline, the benefits of the subsidiary to the Company will be immediate.

  • GlobeNewswire

    Innovation Pharmaceuticals Receives New Patent for Compounds for Use in Treatment of Oral Mucositis

    Innovation Pharmaceuticals, (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent & Trademark Office issued today a new patent to the Company for the treatment of oral mucositis. The new patent broadens the Company’s Intellectual Property footprint in the oral mucositis therapeutic area, and further builds on other recently assigned patent protections for Brilacidin, the Company’s defensin-mimetic drug candidate.

  • GlobeNewswire

    Innovation Pharmaceuticals Files Form 10-Q Quarterly Report

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, announces that on February 8, 2019, it filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarter ended December 31, 2018.  The filing is available on the Company’s website under the “Financials & Filings” tab.

  • GlobeNewswire

    Innovation Pharmaceuticals Establishing European Subsidiary; CEO Increases Equity Stake in IPIX

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, today announces that the Company is establishing a wholly-owned European subsidiary for the purpose of the development of its drug candidates internationally.  Management is pleased to report that, with the Holiday Season now over, discussions have resumed with potential pharmaceutical company partners, both overseas and domestic with a global presence. Licensing interest has been expressed in Brilacidin as a new drug candidate for Oral Mucositis and/or Inflammatory Bowel Disease.

  • GlobeNewswire

    Innovation Pharmaceuticals Announces Clinical Development Plans for Oral Brilacidin for Inflammatory Bowel Disease

    Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce plans to initiate in 2019 a clinical trial of Brilacidin, its novel defensin-mimetic drug candidate, as an oral dosage form. Building upon the successful Phase 2 Proof-of-Concept (PoC) clinical trial for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), the aim of this program is to develop treatment for the more extensive forms of Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn’s Disease.